These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35815690)

  • 1. Understanding ocular comfort differences between 0.7% olopatadine and 0.3% pheniramine maleate/0.025% naphazoline hydrochloride eye drops.
    Lievens C; Pucker AD; McGwin G; Logan A; Franklin Q; Brafford R; Hogan C; Kelley LR; Christensen M
    Clin Exp Optom; 2023 Jul; 106(5):498-502. PubMed ID: 35815690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining initial ocular comfort differences between 0.7% olopatadine and 0.035% ketotifen fumarate.
    Logan A; Pucker AD; Franklin Q; McGwin G; Hogan C; Kelley LR; Christensen M; Brafford R; Lievens C
    Cont Lens Anterior Eye; 2023 Apr; 46(2):101769. PubMed ID: 36195538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV; Udell IJ
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review.
    Zi Y; Deng Y; Ji M; Qin Y; Nong L; Liu Z; Jin M
    Medicine (Baltimore); 2020 Feb; 99(7):e18618. PubMed ID: 32049778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
    Butrus S; Greiner JV; Discepola M; Finegold I
    Clin Ther; 2000 Dec; 22(12):1462-72. PubMed ID: 11192137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A; Abelson MB
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A multicenter, double-masked, randomized evaluation of olopatadine 0.2% using the conjunctival allergen challenge model in Japanese patients with allergic conjunctivitis].
    Ohno S;
    Nippon Ganka Gakkai Zasshi; 2012 Dec; 116(12):1123-9. PubMed ID: 23379201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops.
    Uchio E
    Clin Ophthalmol; 2008 Sep; 2(3):525-31. PubMed ID: 19668750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies.
    Epstein AB; Van Hoven PT; Kaufman A; Carr WW
    Clin Ophthalmol; 2009; 3():329-36. PubMed ID: 19668586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
    Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
    Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of olopatadine for the treatment of ocular allergy.
    Abelson MB
    Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB; Lanier RQ
    Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
    Yaylali V; Demirlenk I; Tatlipinar S; Ozbay D; Esme A; Yildirim C; Ozden S
    Acta Ophthalmol Scand; 2003 Aug; 81(4):378-82. PubMed ID: 12859265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis].
    Endre L; Hidasi V
    Orv Hetil; 2006 Sep; 147(36):1741-3. PubMed ID: 17087018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
    Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
    Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.
    Abelson MB; Gomes PJ
    Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):453-61. PubMed ID: 18433347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and acceptability of nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis.
    Alexander M; Allegro S; Hicks A
    Adv Ther; 2000; 17(3):140-7. PubMed ID: 11183450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].
    Hida WT; Nogueira DC; Schaefer A; Dantas PE; Dantas MC
    Arq Bras Oftalmol; 2006; 69(6):851-6. PubMed ID: 17273679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.